Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Morgan RD, Clamp AR, Evans DGR, Edmondson RJ, Jayson GC. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. Cancer Chemother Pharmacol. 2018;81(4):647–658. doi:10.1007/s00280-018-3532-929464354
   PubMed Web of Science ®Google Scholar
• Merritt MA, Rice MS, Barnard ME, et al. Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study. Lancet Oncol. 2018;19(8):1107–1116. doi:10.1016/S1470-2045(18)30373-530029888
   PubMed Web of Science ®Google Scholar
• Quinn JE, Carser JE, James CR, Kennedy RD, Harkin DP. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol. 2009;113(1):134–142. doi:10.1016/j.ygyno.2008.12.01519168207
   PubMed Web of Science ®Google Scholar
• Giannopoulou L, Kasimir-Bauer S, Lianidou ES. Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA. Clin Chem Lab Med. 2018;56(2):186–197. doi:10.1515/cclm-2017-001928753534
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. Transl Oncol. 2010;3(1):1–12. doi:10.1593/tlo.0925020165689
   PubMed Web of Science ®Google Scholar
• Della Pepa C, Tonini G, Santini D, et al. Low grade serous ovarian carcinoma: from the molecular characterization to the best therapeutic strategy. Cancer Treat Rev. 2015;41(2):136–143. doi:10.1016/j.ctrv.2014.12.00325573350
   PubMed Web of Science ®Google Scholar
• Sadlecki P, Antosik P, Grzanka D, Grabiec M, Walentowicz-Sadlecka M. KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system. Tumour Biol. 2017;39(10):1010428317733984. doi:10.1177/101042831773398428992761
   PubMedGoogle Scholar
• Morikawa A, Hayashi T, Shimizu N, et al. PIK3CA and KRAS mutations in cell free circulating DNA are useful markers for monitoring ovarian clear cell carcinoma. Oncotarget. 2018;9(20):15266–15274. doi:10.18632/oncotarget.2455529632642
   PubMedGoogle Scholar
• Testa U, Petrucci E, Pasquini L, Castelli G, Pelosi E. Ovarian cancers: genetic abnormalities, tumor heterogeneity and progression, clonal evolution and cancer stem cells. Medicines. 2018;5:1. doi:10.3390/medicines5010016
   Google Scholar
• Cole AJ, Dwight T, Gill AJ, et al. Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Sci Rep. 2016;6:26191. doi:10.1038/srep2619127189670
   PubMed Web of Science ®Google Scholar
• Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 2000;60:5.
   Web of Science ®Google Scholar
• Zak K, Pecak A, Rys B, et al. Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011 – present). Expert Opin Ther Pat. 2013;23(4):425–448. doi:10.1517/13543776.2013.76540523374098
   PubMed Web of Science ®Google Scholar
• Lee JG, Ahn JH, Jin Kim T, Ho lee J, Choi JH. Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin beta4 and Akt signals. Sci Rep. 2015;5:12642. doi:10.1038/srep1264226223322
   PubMed Web of Science ®Google Scholar
• Davaadelger B, Shen H, Maki CG. Novel roles for p53 in the genesis and targeting of tetraploid cancer cells. PLoS One. 2014;9(11):e110844. doi:10.1371/journal.pone.011084425380055
   PubMed Web of Science ®Google Scholar
• Wu GS, Ding Z. Caspase 9 is required for p53-dependent apoptosis and chemosensitivity in a human ovarian cancer cell line. Oncogene. 2002;21:1–8. doi:10.1038/sj.onc.120502011791171
   PubMed Web of Science ®Google Scholar
• Kitayner M, Rozenberg H, Kessler N, et al. Structural basis of DNA recognition by p53 tetramers. Mol Cell. 2006;22(6):741–753. doi:10.1016/j.molcel.2006.05.01516793544
   PubMed Web of Science ®Google Scholar
• Duffy MJ, Synnott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer. 2017;83:258–265. doi:10.1016/j.ejca.2017.06.02328756138
   PubMed Web of Science ®Google Scholar
• Padmanabhan A, Candelaria N, Wong KK, et al. USP15-dependent lysosomal pathway controls p53-R175H turnover in ovarian cancer cells. Nat Commun. 2018;9(1):1270. doi:10.1038/s41467-018-03599-w29593334
   PubMed Web of Science ®Google Scholar
• Yang-Hartwich Y, Soteras MG, Lin ZP, et al. p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene. 2015;34(27):3605–3616. doi:10.1038/onc.2014.29625263447
   PubMed Web of Science ®Google Scholar
• Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions. Drug Resist Updat. 2016;24:55–69. doi:10.1016/j.drup.2015.11.00526830315
   PubMed Web of Science ®Google Scholar
• Kang HJ, Chun SM, Kim KR, Sohn I, Sung CO. Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma. PLoS One. 2013;8(8):e72609. doi:10.1371/journal.pone.007260923967324
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49–56. doi:10.1002/path.269620229506
   PubMed Web of Science ®Google Scholar
• Ahn JH, Kim TJ, Lee JH, Choi JH. Mutant p53 stimulates cell invasion through an interaction with Rad21 in human ovarian cancer cells. Sci Rep. 2017;7(1):9076. doi:10.1038/s41598-017-08880-428831167
   PubMed Web of Science ®Google Scholar
• Hofstetter G, Berger A, Fiegl H, et al. Alternative splicing of p53 and p73: the novel p53 splice variant p53delta is an independent prognostic marker in ovarian cancer. Oncogene. 2010;29(13):1997–2004. doi:10.1038/onc.2009.48220101229
   PubMed Web of Science ®Google Scholar
• Alaee M, Danesh G, Pasdar M. Plakoglobin reduces the in vitro growth, migration and invasion of ovarian cancer cells expressing N-cadherin and mutant p53. PLoS One. 2016;11(5):e0154323. doi:10.1371/journal.pone.015432327144941
   PubMed Web of Science ®Google Scholar
• Emmanuel C, Chiew YE, George J, et al. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Clin Cancer Res. 2014;20(24):6618–6630. doi:10.1158/1078-0432.CCR-14-129225316818
   PubMed Web of Science ®Google Scholar
• Sonego M, Schiappacassi M, Lovisa S, et al. Stathmin regulates mutant p53 stability and transcriptional activity in ovarian cancer. EMBO Mol Med. 2013;5(5):707–722. doi:10.1002/emmm.20120150423610071
   PubMed Web of Science ®Google Scholar
• Brachova P, Thiel KW, Leslie KK. The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci. 2013;14(9):19257–19275. doi:10.3390/ijms14091925724065105
   PubMed Web of Science ®Google Scholar
• Machado-Silva A, Perrier S, Bourdon JC. p53 family members in cancer diagnosis and treatment. Semin Cancer Biol. 2010;20(1):57–62. doi:10.1016/j.semcancer.2010.02.00520206267
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E. New treatments in ovarian cancer. Ann Oncol. 2017;28(suppl_8):viii57–viii60. doi:10.1093/annonc/mdx44229232465
   PubMed Web of Science ®Google Scholar
• Bykov VJ, Zhang Q, Zhang M, Ceder S, Abrahmsen L, Wiman KG. Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy. Front Oncol. 2016;6:21. doi:10.3389/fonc.2016.0002126870698
   PubMed Web of Science ®Google Scholar
• Soragni A, Janzen DM, Johnson LM, et al. A designed inhibitor of p53 aggregation rescues p53 tumor suppression in ovarian carcinomas. Cancer Cell. 2016;29(1):90–103. doi:10.1016/j.ccell.2015.12.00226748848
   PubMed Web of Science ®Google Scholar
• Oda K, Ikeda Y, Kashiyama T, et al. Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies. J Obstet Gynaecol Res. 2016;42(7):757–762. doi:10.1111/jog.1301827094348
   PubMed Web of Science ®Google Scholar
• Amin A, Karpowicz PA, Carey TE, et al. Evasion of anti-growth signaling: a key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds. Semin Cancer Biol. 2015;35(Suppl):S55–S77.25749195
   PubMed Web of Science ®Google Scholar
• Zanjirband M, Edmondson RJ, Lunec J. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer. Oncotarget. 2016;7:26. doi:10.18632/oncotarget.9499
   Google Scholar
• Zhang Q, Zeng SX, Lu H. Targeting p53-MDM2-MDMX loop for cancer therapy. Subcell Biochem. 2014;85:281–319.25201201
   PubMedGoogle Scholar
• Duffy MJ, Synnott NC, McGowan PM, Crown J, O’Connor D, Gallagher WM. p53 as a target for the treatment of cancer. Cancer Treat Rev. 2014;40(10):1153–1160. doi:10.1016/j.ctrv.2014.10.00425455730
   PubMed Web of Science ®Google Scholar
• Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844–848. doi:10.1126/science.109247214704432
   PubMed Web of Science ®Google Scholar
• Yang Y, Ludwig RL, Jensen JP, et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell. 2005;7(6):547–559. doi:10.1016/j.ccr.2005.04.02915950904
   PubMed Web of Science ®Google Scholar
• Herman AG, Hayano M, Poyurovsky MV, et al. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discov. 2011;1(4):312–325. doi:10.1158/2159-8290.CD-11-010422586610
   PubMed Web of Science ®Google Scholar
• Kojima K, Burks JK, Arts J, Andreeff M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther. 2010;9(9):2545–2557. doi:10.1158/1535-7163.MCT-10-033720736344
   PubMed Web of Science ®Google Scholar
• Schilling D, Düwel M, Molls M, Multhoff G. Radiosensitization of wildtype p53 cancer cells by the MDM2-inhibitor PXN727 is associated with altered heat shock protein 70 (Hsp70) levels. Cell Stress Chaperones. 2012;18(2):183–191. doi:10.1007/s12192-012-0369-822933182
   PubMed Web of Science ®Google Scholar
• Roth JA. Adenovirus p53 gene therapy. Expert Opin Biol Ther. 2005;6(1):55–61. doi:10.1517/14712598.6.1.55
   Web of Science ®Google Scholar
• Dai L, Pan Q, Peng Y, et al. p53 plays a key role in the apoptosis of human ovarian cancer cells induced by adenovirus-mediated CRM197. Hum Gene Ther. 2018;29(8):916–926. doi:10.1089/hum.2017.18629620944
   PubMed Web of Science ®Google Scholar
• Liu Q, Sui R, Li R, Miao J, Liu J. Biological characteristics of Taxolresistant ovarian cancer cells and reversal of Taxol resistance by adenovirus expressing p53. Mol Med Rep. 2015;11(2):1292–1297. doi:10.3892/mmr.2014.278425351378
   PubMed Web of Science ®Google Scholar
• Wang J, Gao Q, Li Q. Adenovirus type 12 E1B 55-kilodalton oncoprotein promotes p53-mediated apoptotic response of ovarian cancer to cisplatin. Tumor Biol. 2015;36(8):6569–6577. doi:10.1007/s13277-015-3351-0
   PubMedGoogle Scholar
• Chira S, Gulei D, Hajitou A, Zimta AA, Cordelier P, Berindan-Neagoe I. CRISPR/Cas9: transcending the reality of genome editing. Mol Ther Nucleic Acids. 2017;7:211–222. doi:10.1016/j.omtn.2017.04.00128624197
   PubMedGoogle Scholar
• Liu C, Zhang L, Liu H, Cheng K. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. J Control Release. 2017;266:17–26. doi:10.1016/j.jconrel.2017.09.01228911805
   PubMed Web of Science ®Google Scholar
• Savic N, Schwank G. Advances in therapeutic CRISPR/Cas9 genome editing. Transl Res. 2016;168:15–21. doi:10.1016/j.trsl.2015.09.00826470680
   PubMed Web of Science ®Google Scholar
• Walton J, Blagih J, Ennis D, et al. CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma. Cancer Res. 2016;76(20):6118–6129. doi:10.1158/0008-5472.CAN-16-127227530326
   PubMed Web of Science ®Google Scholar
• Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2011;12(1):68–78. doi:10.1038/nrc318122193408
   PubMed Web of Science ®Google Scholar
• Girolimetti G, Perrone AM, Santini D, et al. BRCA-associated ovarian cancer: from molecular genetics to risk management. Biomed Res Int. 2014;2014:787143. doi:10.1155/2014/78714325136623
   PubMed Web of Science ®Google Scholar
• Gadducci A, Guarneri V, Peccatori FA, et al. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status. J Ovarian Res. 2019;12(1):9. doi:10.1186/s13048-019-0484-630691488
   PubMed Web of Science ®Google Scholar
• Lubinski J, Phelan CM, Ghadirian P, et al. Cancer variation associated with the position of the mutation in the BRCA2 gene. Fam Cancer. 2004;3(1):1–10. doi:10.1023/B:FAME.0000026816.32400.4515131399
   PubMedGoogle Scholar
• Plaskocinska I, Shipman H, Drummond J, et al. New paradigms for BRCA1/BRCA2 testing in women with ovarian cancer: results of the genetic testing in epithelial ovarian cancer (GTEOC) study. J Med Genet. 2016;53(10):655–661. doi:10.1136/jmedgenet-2016-10390227208206
   PubMed Web of Science ®Google Scholar
• Rust K, Spiliopoulou P, Tang CY, et al. Routine germline BRCA1 and BRCA2 testing in patients with ovarian carcinoma: analysis of the Scottish real-life experience. BJOG. 2018;125(11):1451–1458. doi:10.1111/1471-0528.1517129460478
   PubMed Web of Science ®Google Scholar
• Morgan RD, Burghel GJ, Flaum N, et al. Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases. J Med Genet. 2019;56(5):301–307. doi:10.1136/jmedgenet-2018-10579230683677
   PubMed Web of Science ®Google Scholar
• Harter P, Hauke J, Heitz F, et al. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS One. 2017;12(10):e0186043. doi:10.1371/journal.pone.018604329053726
   PubMed Web of Science ®Google Scholar
• Krivokuca A, Boljevic I, Jovandic S, et al. Germline mutations in cancer susceptibility genes in high grade serous ovarian cancer in Serbia. J Hum Genet. 2019;64(4):281–290. doi:10.1038/s10038-019-0562-z30651582
   PubMed Web of Science ®Google Scholar
• Tsibulak I, Wieser V, Degasper C, et al. BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer. Br J Cancer. 2018;119(6):683–692. doi:10.1038/s41416-018-0217-430111871
   PubMed Web of Science ®Google Scholar
• Edwards SL, Brough R, Lord CJ, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008;451(7182):1111–1115. doi:10.1038/nature0654818264088
   PubMed Web of Science ®Google Scholar
• Sakai W, Swisher EM, Karlan BY, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451(7182):1116–1120. doi:10.1038/nature0663318264087
   PubMed Web of Science ®Google Scholar
• Biglia N, Sgandurra P, Bounous VE, et al. Ovarian cancer in BRCA1 and BRCA2 gene mutation carriers: analysis of prognostic factors and survival. Ecancermedicalscience. 2016;10:639. doi:10.3332/ecancer.2016.63927350785
   PubMed Web of Science ®Google Scholar
• Hyman DM, Zhou Q, Iasonos A, et al. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer. 2012;118(15):3703–3709. doi:10.1002/cncr.2665522139894
   PubMed Web of Science ®Google Scholar
• Liu X, Shi Y, Maag DX, et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin Cancer Res. 2012;18(2):510–523. doi:10.1158/1078-0432.CCR-11-197322128301
   PubMed Web of Science ®Google Scholar
• Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol. 2014;133(2):362–369. doi:10.1016/j.ygyno.2014.02.03924607283
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72(21):5588–5599. doi:10.1158/0008-5472.CAN-12-275323118055
   PubMed Web of Science ®Google Scholar
• Brown JS, Kaye SB, Yap TA. PARP inhibitors: the race is on. Br J Cancer. 2016;114(7):713–715. doi:10.1038/bjc.2016.6727022824
   PubMed Web of Science ®Google Scholar
• Damia G, Sessa C. Successes and limitations of targeted cancer therapy in ovarian cancer. Prog Tumor Res. 2014;41:89–97.24727989
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–615. doi:10.1038/nature1016621720365
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–921. doi:10.1038/nature0344515829967
   PubMed Web of Science ®Google Scholar
• Kaelin WG. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5(9):689–698. doi:10.1038/nrc169116110319
   PubMed Web of Science ®Google Scholar
• Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010;376(9737):245–251. doi:10.1016/S0140-6736(10)60893-820609468
   PubMed Web of Science ®Google Scholar
• Meehan RS, Chen AP. New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract. 2016;3:3. doi:10.1186/s40661-016-0024-727231574
   PubMedGoogle Scholar
• Ledermann JA. PARP inhibitors in ovarian cancer. Ann Oncol. 2016;27(Suppl 1):i40–i44. doi:10.1093/annonc/mdw09427141070
   PubMed Web of Science ®Google Scholar
• Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579–1589. doi:10.1016/S1470-2045(16)30376-X27617661
   PubMed Web of Science ®Google Scholar
• Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–1284. doi:10.1016/S1470-2045(17)30469-228754483
   PubMed Web of Science ®Google Scholar
• Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–2164. doi:10.1056/NEJMoa161131027717299
   PubMed Web of Science ®Google Scholar
• Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–1961. doi:10.1016/S0140-6736(17)32440-628916367
   PubMed Web of Science ®Google Scholar
• Nijman SM. Synthetic lethality: general principles, utility and detection using genetic screens in human cells. FEBS Lett. 2011;585(1):1–6. doi:10.1016/j.febslet.2010.11.02421094158
   PubMed Web of Science ®Google Scholar
• Miller RE, Ledermann JA. The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib. Clin Adv Hematol Oncol. 2016;14(8):619–627.27487106
   PubMed Web of Science ®Google Scholar
• Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL. Reversion of BRCA1/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol. 2017;35(12):1274–1280. doi:10.1200/JCO.2016.70.462728414925
   PubMed Web of Science ®Google Scholar
• Lin KK, Harrell MI, Oza AM, et al. BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma. Cancer Discov. 2019;9(2):210–219. doi:10.1158/2159-8290.CD-18-071530425037
   PubMed Web of Science ®Google Scholar
• Weigelt B, Comino-Mendez I, de Bruijn I, et al. Diverse BRCA1 and BRCA2 reversion mutations in circulating cell-free DNA of therapy-resistant breast or ovarian cancer. Clin Cancer Res. 2017;23(21):6708–6720. doi:10.1158/1078-0432.CCR-17-054428765325
   PubMed Web of Science ®Google Scholar
• Wang Y, Bernhardy AJ, Cruz C, et al. The BRCA1-Delta11q alternative splice isoform bypasses germline mutations and promotes therapeutic resistance to PARP inhibition and cisplatin. Cancer Res. 2016;76(9):2778–2790. doi:10.1158/0008-5472.CAN-16-018627197267
   PubMed Web of Science ®Google Scholar
• Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012;2(11):1048–1063. doi:10.1158/2159-8290.CD-11-033622915751
   PubMed Web of Science ®Google Scholar
• Wang D, Wang M, Jiang N, Zhang Y, Bian X. Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. Oncotarget. 2016;7:14.
   Google Scholar
• Oishi T, Itamochi H, Kudoh A, et al. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma. Oncol Rep. 2014;32(2):553–558. doi:10.3892/or.2014.326824927217
   PubMed Web of Science ®Google Scholar
• Thakur B, Ray P. p53 loses grip on PIK3CA expression leading to enhanced cell survival during platinum resistance. Mol Oncol. 2016;10(8):1283–1295. doi:10.1016/j.molonc.2016.06.00627401370
   PubMed Web of Science ®Google Scholar
• Heudel PE, Fabbro M, Roemer-Becuwe C, et al. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group. Br J Cancer. 2017;116(3):303–309. doi:10.1038/bjc.2016.43028072765
   PubMed Web of Science ®Google Scholar
• Gungor H, Saleem A, Babar S, et al. Dose-finding quantitative 18F-FDG PET imaging study with the oral pan-AKT inhibitor GSK2141795 in patients with gynecologic malignancies. J Nucl Med. 2015;56(12):1828–1835. doi:10.2967/jnumed.115.15650526429956
   PubMed Web of Science ®Google Scholar
• Zannoni GF, Improta G, Pettinato A, et al. Molecular status of PI3KCA, KRAS and BRAF in ovarian clear cell carcinoma: an analysis of 63 patients. J Clin Pathol. 2016;69(12):1088–1092. doi:10.1136/jclinpath-2016-20377627153872
   PubMed Web of Science ®Google Scholar
• Wang D, Li C, Zhang Y, et al. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecol Oncol. 2016;142(3):548–556. doi:10.1016/j.ygyno.2016.07.09227426307
   PubMed Web of Science ®Google Scholar
• Despierre E, Yesilyurt BT, Lambrechts S, et al. Epithelial ovarian cancer rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment. Int J Gynecol Cancer. 2014;24:10. doi:10.1097/IGC.0000000000000089
   Web of Science ®Google Scholar
• Samartzis EP, Noske A, Dedes KJ, et al. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci. 2013;14:18824–18849.24036443
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Yamazaki M, Takahashi H, et al. Distinct β-Catenin and PIK3CA mutation profiles in endometriosis-associated ovarian endometrioid and clear cell carcinomas. Am J Clin Pathol. 2015;144(3):452–463. doi:10.1309/AJCPZ5T2POOFMQVN26276776
   PubMed Web of Science ®Google Scholar
• Friedlander ML, Russell K, Millis S, Gatalica Z, Bender R, Voss A. Molecular profiling of clear cell ovarian cancers: identifying potential treatment targets for clinical trials. Int J Gynecol Cancer. 2016;26(4):648–654. doi:10.1097/IGC.000000000000067726937756
   PubMed Web of Science ®Google Scholar
• Murakami R, Matsumura N, Brown JB, et al. Exome sequencing landscape analysis in ovarian clear cell carcinoma shed light on key chromosomal regions and mutation gene networks. Am J Pathol. 2017;187(10):2246–2258. doi:10.1016/j.ajpath.2017.06.01228888422
   PubMed Web of Science ®Google Scholar
• Zannoni GF, Improta G, Chiarello G, et al. Mutational status of KRAS, NRAS, and BRAF in primary clear cell ovarian carcinoma. Virchows Arch. 2014;465(2):193–198. doi:10.1007/s00428-014-1599-124889043
   PubMed Web of Science ®Google Scholar
• Despierre E, Yesilyurt BT, Lambrechts S, et al. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment. Int J Gynecol Cancer. 2014;24(3):468–477.24557434
   PubMed Web of Science ®Google Scholar
• Samartzis EP, Noske A, Dedes KJ, Fink D, Imesch P. ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas. Int J Mol Sci. 2013;14(9):18824–18849. doi:10.3390/ijms14091882424036443
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Tsuda H, Takano M, Tamai S, Matsubara O. Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations. Mod Pathol. 2012;25(4):615–624. doi:10.1038/modpathol.2011.18922157930
   PubMed Web of Science ®Google Scholar
• Kolasa IK, Rembiszewska A, Felisiak A, et al. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther. 2009;8(1):21–26. doi:10.4161/cbt.8.1.720919029838
   PubMed Web of Science ®Google Scholar
• Fu S, Hennessy BT, Ng CS, et al. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012;126(1):47–53. doi:10.1016/j.ygyno.2012.04.00622487539
   PubMed Web of Science ®Google Scholar
• Behbakht K, Sill MW, Darcy KM, et al. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a gynecologic oncology group study. Gynecol Oncol. 2011;123(1):19–26. doi:10.1016/j.ygyno.2011.06.02221752435
   PubMed Web of Science ®Google Scholar
• Zhang Y-J, Duan Y, Zheng XFS. Targeting the mTOR kinase domain: the second generation of mTOR inhibitors. Drug Discov Today. 2011;16(7–8):325–331. doi:10.1016/j.drudis.2011.02.00821333749
   PubMed Web of Science ®Google Scholar
• Cheaib B, Auguste A, Leary A. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer. 2015;34(1):4–16. doi:10.5732/cjc.014.1028925556614
   PubMedGoogle Scholar
• Takano M, Kikuchi Y, Kudoh K, et al. Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases. Int J Clin Oncol. 2011;16(5):605–609. doi:10.1007/s10147-010-0177-z21243393
   PubMed Web of Science ®Google Scholar
• Sarker D, Ang JE, Baird R, et al. First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2015;21(1):77–86. doi:10.1158/1078-0432.CCR-14-094725370471
   PubMed Web of Science ®Google Scholar
• Bowles DW, Ma WW, Senzer N, et al. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer. 2013;109(5):1085–1092. doi:10.1038/bjc.2013.47423942080
   PubMed Web of Science ®Google Scholar
• Gocher AM, Azabdaftari G, Euscher LM, et al. Akt activation by Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells. J Biol Chem. 2017;292(34):14188–14204. doi:10.1074/jbc.M117.77846428634229
   PubMed Web of Science ®Google Scholar
• Patnaik A, Appleman LJ, Tolcher AW, et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Ann Oncol. 2016;27(10):1928–1940. doi:10.1093/annonc/mdw28227672108
   PubMed Web of Science ®Google Scholar
• Cheraghchi-Bashi A, Parker CA, Curry E, et al. A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway. Oncotarget. 2015;6:14. doi:10.18632/oncotarget.6153
   Google Scholar
• Tsuchida N, Murugan AK, Grieco M. Kirsten Ras oncogene: significance of its discovery in human cancer research. Oncotarget. 2016;7(29):46717–46733. doi:10.18632/oncotarget.877327102293
   PubMed Web of Science ®Google Scholar
• Tsai FD, Lopes MS, Zhou M, et al. K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif. Proc Natl Acad Sci U S A. 2015;112(3):779–784. doi:10.1073/pnas.141281111225561545
   PubMed Web of Science ®Google Scholar
• Hollestelle A, Pelletier C, Hooning M, et al. Prevalence of the variant allele rs61764370 T>G in the 3ʹUTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families. Breast Cancer Res Treat. 2011;128(1):79–84. doi:10.1007/s10549-010-1080-z20676756
   PubMed Web of Science ®Google Scholar
• Sakai K, Ukita M, Schmidt J, et al. Clonal composition of human ovarian cancer based on copy number analysis reveals a reciprocal relation with oncogenic mutation status. Cancer Lett. 2017;405:22–28. doi:10.1016/j.canlet.2017.07.01328734796
   PubMed Web of Science ®Google Scholar
• Boyd J, Luo B, Peri S, et al. Whole exome sequence analysis of serous borderline tumors of the ovary. Gynecol Oncol. 2013;130(3):560–564. doi:10.1016/j.ygyno.2013.06.00723774303
   PubMed Web of Science ®Google Scholar
• Rechsteiner M, Zimmermann AK, Wild PJ, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol. 2013;95(2):235–241. doi:10.1016/j.yexmp.2013.08.00423965232
   PubMed Web of Science ®Google Scholar
• Kim SI, Lee JW, Lee M, et al. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing. Gynecol Oncol. 2018;148(2):375–382. doi:10.1016/j.ygyno.2017.12.00529233531
   PubMed Web of Science ®Google Scholar
• Koshiyama M, Matsumura N, Konishi I. Recent concepts of ovarian carcinogenesis: type I and type II. Biomed Res Int. 2014;2014:934261. doi:10.1155/2014/93426124868556
   PubMed Web of Science ®Google Scholar
• Lee YJ, Lee MY, Ruan A, et al. Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms. Oncotarget. 2016;7(50):82097–82103. doi:10.18632/oncotarget.1344927888800
   PubMedGoogle Scholar
• Garrett AP, Lee KR, Colitti CR, Muto MG, Berkowitz RS, Mok SC. k-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol. 2001;20(3):244–251. doi:10.1097/00004347-200107000-0000711444200
   PubMed Web of Science ®Google Scholar
• Li XS, Sun J, He XL. Expression of c-myc and mutation of the KRAS gene in patients with ovarian mucinous tumors. Genet Mol Res. 2015;14(3):10752–10759. doi:10.4238/2015.September.9.1426400304
   PubMed Web of Science ®Google Scholar
• Mackenzie R, Kommoss S, Winterhoff BJ, et al. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer. 2015;15:415. doi:10.1186/s12885-015-1421-825986173
   PubMed Web of Science ®Google Scholar
• Stephen AG, Esposito D, Bagni RK, McCormick F. Dragging ras back in the ring. Cancer Cell. 2014;25(3):272–281. doi:10.1016/j.ccr.2014.02.01724651010
   PubMed Web of Science ®Google Scholar
• Pang X, Liu M. Defeat mutant KRAS with synthetic lethality. Small GTPases. 2016;8(4):212–219. doi:10.1080/21541248.2016.121378327463838
   PubMedGoogle Scholar
• Zeitouni D, Pylayeva-Gupta Y, Der CJ, Bryant KL. KRAS mutant pancreatic cancer: no lone path to an effective treatment. Cancers. 2016;8(4):45. doi:10.3390/cancers8040045
   PubMed Web of Science ®Google Scholar
• Lito P, Solomon M, Li LS, Hansen R, Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science. 2016;351(6273):604–608. doi:10.1126/science.aad620426841430
   PubMed Web of Science ®Google Scholar
• Pecot CV, Wu SY, Bellister S, et al. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther. 2014;13(12):2876–2885. doi:10.1158/1535-7163.MCT-14-007425281617
   PubMed Web of Science ®Google Scholar
• Kamerkar S, LeBleu VS, Sugimoto H, et al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 2017;546(7659):498–503. doi:10.1038/nature2234128607485
   PubMed Web of Science ®Google Scholar
• Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13(5):1576–1583. doi:10.1158/1078-0432.CCR-06-115017332304
   PubMed Web of Science ®Google Scholar
• Spreafico A, Oza AM, Clarke BA, et al. Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC). Gynecol Oncol. 2017;144(2):250–255. doi:10.1016/j.ygyno.2016.12.00228062115
   PubMed Web of Science ®Google Scholar
• Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod SA. Low-grade serous ovarian cancer: a review. Gynecol Oncol. 2016;143(2):433–438. doi:10.1016/j.ygyno.2016.08.32027581327
   PubMed Web of Science ®Google Scholar
• Costa-Cabral S, Brough R, Konde A, et al. CDK1 is a synthetic lethal target for KRAS mutant tumours. PLoS One. 2016;11(2):e0149099. doi:10.1371/journal.pone.014909926881434
   PubMed Web of Science ®Google Scholar
• Inaba K, Oda K, Aoki K, et al. Synergistic antitumor effects of combination PI3K/mTOR and MEK inhibition (SAR245409 and pimasertib) in mucinous ovarian carcinoma cells by fluorescence resonance energy transfer imaging. Oncotarget. 2016;7(20):29577–29591. doi:10.18632/oncotarget.880727102436
   PubMedGoogle Scholar
• de Castro Carpeno J, Belda-Iniesta C. KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach. Transl Lung Cancer Res. 2013;2(2):142–151. doi:10.3978/j.issn.2218-6751.2013.02.0725806225
   PubMedGoogle Scholar
• Otsuka J, Okuda T, Sekizawa A, et al. Detection of p53 mutations in the plasma DNA of patients with ovarian cancer. Int J Gynecol Cancer. 2004;14(3):459–464. doi:10.1111/j.1048-891x.2004.014305.x15228418
   PubMed Web of Science ®Google Scholar
• Parkinson CA, Gale D, Piskorz AM, et al. Exploratory analysis of TP53 mutations in circulating tumour DNA as biomarkers of treatment response for patients with relapsed high-grade serous ovarian carcinoma: a retrospective study. PLoS Med. 2016;13(12):e1002198. doi:10.1371/journal.pmed.100219827997533
   PubMed Web of Science ®Google Scholar
• Mayor P, Gay LM, Lele S, Elvin JA. BRCA1 reversion mutation acquired after treatment identified by liquid biopsy. Gynecol Oncol Rep. 2017;21:57–60. doi:10.1016/j.gore.2017.06.01028706968
   PubMed Web of Science ®Google Scholar
• Giannopoulou L, Zavridou M, Kasimir-Bauer S, Lianidou ES. Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes. Transl Res. 2019;205:77–91. doi:10.1016/j.trsl.2018.10.00330391474
   PubMed Web of Science ®Google Scholar
• Pennington KP, Walsh T, Harrell MI, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20(3):764–775. doi:10.1158/1078-0432.CCR-13-228724240112
   PubMed Web of Science ®Google Scholar
• Nakamura K, Nakayama K, Ishikawa N, et al. Reconstitution of high-grade serous ovarian carcinoma from primary fallopian tube secretory epithelial cells. Oncotarget. 2018;9(16):12609–12619. doi:10.18632/oncotarget.2303529560094
   PubMedGoogle Scholar
• Marchetti C, De Leo R, Musella A, et al. BRCA mutation status to personalize management of recurrent ovarian cancer: a multicenter study. Ann Surg Oncol. 2018;25(12):3701–3708. doi:10.1245/s10434-018-6700-630128899
   PubMed Web of Science ®Google Scholar
• Singer G, Stohr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29(2):218–224. doi:10.1097/01.pas.0000146025.91953.8d15644779
   PubMed Web of Science ®Google Scholar
• Jones S, Wang TL, Kurman RJ, et al. Low-grade serous carcinomas of the ovary contain very few point mutations. J Pathol. 2012;226(3):413–420. doi:10.1002/path.396722102435
   PubMed Web of Science ®Google Scholar
• Liu J, Westin SN. Rational selection of biomarker driven therapies for gynecologic cancers: the more we know, the more we know we don’t know. Gynecol Oncol. 2016;141(1):65–71. doi:10.1016/j.ygyno.2016.01.00327016231
   PubMed Web of Science ®Google Scholar
• Jean S, Li J, Katsaros D, et al. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations. Oncotarget. 2016;7(30):48577–48585. doi:10.18632/oncotarget.937327191893
   PubMedGoogle Scholar
• Ho ES, Lai CR, Hsieh YT, et al. p53 mutation is infrequent in clear cell carcinoma of the ovary. Gynecol Oncol. 2001;80(2):189–193. doi:10.1006/gyno.2000.602511161858
   PubMed Web of Science ®Google Scholar
• Shi T, Wang P, Tang W, et al. Survival benefit of germline BRCA mutation is associated with residual disease in ovarian cancer. Cell Physiol Biochem. 2018;47(5):2088–2096. doi:10.1159/00049147729975922
   PubMedGoogle Scholar
• Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121(2):353–357. doi:10.1016/j.ygyno.2011.01.02021324516
   PubMed Web of Science ®Google Scholar
• Fransson A, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N. Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant high-grade serous ovarian cancer. J Ovarian Res. 2016;9(1):27. doi:10.1186/s13048-016-0239-627179933
   PubMed Web of Science ®Google Scholar
• Leijen S, van Geel RM, Sonke GS, et al. Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol. 2016;34(36):4354–4361. doi:10.1200/JCO.2016.67.594227998224
   PubMed Web of Science ®Google Scholar
• Wolf JK, Bodurka DC, Gano JB, et al. A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. Gynecol Oncol. 2004;94(2):442–448. doi:10.1016/j.ygyno.2004.05.04115297186
   PubMed Web of Science ®Google Scholar
• Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol. 2002;20(6):1562–1569. doi:10.1200/JCO.2002.20.6.156211896105
   PubMed Web of Science ®Google Scholar
• Buller RE, Runnebaum IB, Karlan BY, et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 2002;9(7):553–566. doi:10.1038/sj.cgt.770047212082455
   PubMed Web of Science ®Google Scholar
• Usha L, Sill MW, Darcy KM, et al. A gynecologic oncology group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. Gynecol Oncol. 2011;121(3):455–461. doi:10.1016/j.ygyno.2011.02.01321414654
   PubMed Web of Science ®Google Scholar
• Mir R, Tortosa A, Martinez-Soler F, et al. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells. Int J Cancer. 2013;132(7):1525–1536. doi:10.1002/ijc.2783222961628
   PubMed Web of Science ®Google Scholar
• Makii C, Oda K, Ikeda Y, et al. MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53. Oncotarget. 2016;7(46):75328–75338. doi:10.18632/oncotarget.1217527659536
   PubMedGoogle Scholar
• Coleman RL, Sill MW, Bell-McGuinn K, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2015;137(3):386–391. doi:10.1016/j.ygyno.2015.03.04225818403
   PubMed Web of Science ®Google Scholar
• Bell-McGuinn KM, Konner JA, Tew WP, et al. A phase 2, single arm study of iniparib in patients with BRCA1 or BRCA2 associated advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer. 2016;26(2):255–260. doi:10.1097/IGC.000000000000059126745694
   PubMed Web of Science ®Google Scholar
• Matulonis U, Vergote I, Backes F, et al. Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015;136(2):246–253. doi:10.1016/j.ygyno.2014.12.01925528496
   PubMed Web of Science ®Google Scholar
• Schram AM, Gandhi L, Mita MM, et al. A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours. Br J Cancer. 2018;119(12):1471–1476. doi:10.1038/s41416-018-0322-430425349
   PubMed Web of Science ®Google Scholar
• Hasegawa K, Kagabu M, Mizuno M, et al. Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations. Invest New Drugs. 2017;35(6):800–812. doi:10.1007/s10637-017-0504-628864978
   PubMed Web of Science ®Google Scholar
• Angevin E, Tabernero J, Elez E, et al. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res. 2014;20(8):2192–2204. doi:10.1158/1078-0432.CCR-13-220024563479
   PubMed Web of Science ®Google Scholar
• Bedard PL, Tabernero J, Janku F, et al. A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 2015;21(4):730–738. doi:10.1158/1078-0432.CCR-14-181425500057
   PubMed Web of Science ®Google Scholar